Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 3Q

Biopharmaceutical sales were $4.8 billion (+6%)

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 3Q

3Q Revenues: $5.5 billion (+4%)

3Q Earnings: $1.3 billion (-54%)

YTD Revenues: $15.9 billion (+4%)

YTD Earnings: $3.5 billion (-26%)

Comments: Biopharmaceutical sales were $4.8 billion (+6%). Plavix sales were $1.6 billion (+8%). Sales of Abilify were $653 million (+16%). Reyataz sales were $360 million (+5%). Sustiva Franchise revenue was $315 million (+7%). Erbitux sales were down 3% to $179 million. Sprycel sales were up 30% to $107 million. R&D expenses were $820 million in the quarter (+5%). BMS’ share of Mead Johnson’s earnings was $127 million in the quarter (-20%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters